VistaGen Therapeutics Shiller PE Ratio

: (As of Today)

View and export this data going back to 2011. Start your Free Trial

Shiller PE for Stocks: The True Measure of Stock Valuation

VistaGen Therapeutics Shiller PE Ratio Historical Data

The historical data trend for VistaGen Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VistaGen Therapeutics Annual Data

Trend

Mar12

Mar13

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Shiller PE Ratio

VistaGen Therapeutics Quarterly Data
	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
Shiller PE Ratio																-	-	-	-	-

Competitive Comparison

For the Biotechnology subindustry, VistaGen Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

VistaGen Therapeutics Shiller PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, VistaGen Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where VistaGen Therapeutics's Shiller PE Ratio falls into.

VistaGen Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

VistaGen Therapeutics's E10 for the quarter that ended in Dec. 2021 is calculated as:

For example, VistaGen Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2021 was:

Adj_EPS	=	Earnings per Share (Diluted)	/	CPI of Dec. 2021 (Change)	*	Current CPI (Dec. 2021)
	=	-0.05	/	117.6295	*	117.6295
	=	-0.050

Current CPI (Dec. 2021) = 117.6295.

VistaGen Therapeutics Quarterly Data

	Earnings per Share (Diluted)	CPI	Adj_EPS
201203	-3.632	96.783	-4.414
201206	-2.200	96.819	-2.673
201209	-2.400	97.633	-2.892
201212	-17.000	96.871	-20.643
201303	-3.200	98.209	-3.833
201306	-0.400	98.518	-0.478
201309	-1.370	98.790	-1.631
201312	-0.440	98.326	-0.526
201403	-1.640	99.695	-1.935
201406	-3.700	100.560	-4.328
201409	-1.900	100.428	-2.225
201412	-1.080	99.070	-1.282
201503	-4.500	99.621	-5.313
201506	-19.230	100.684	-22.467
201509	-5.260	100.392	-6.163
201512	-1.950	99.792	-2.299
201603	-3.630	100.470	-4.250
201606	-0.510	101.688	-0.590
201609	-0.420	101.861	-0.485
201612	-0.340	101.863	-0.393
201703	-0.310	102.862	-0.355
201706	-0.280	103.349	-0.319
201709	-0.530	104.136	-0.599
201712	-0.250	104.011	-0.283
201803	-0.189	105.290	-0.211
201806	-0.200	106.317	-0.221
201809	-0.300	106.507	-0.331
201812	-0.240	105.998	-0.266
201903	-0.150	107.251	-0.165
201906	-0.150	108.070	-0.163
201909	-0.130	108.329	-0.141
201912	-0.150	108.420	-0.163
202003	-0.070	108.902	-0.076
202006	-0.070	108.767	-0.076
202009	-0.050	109.815	-0.054
202012	-0.070	109.897	-0.075
202103	-0.164	111.754	-0.173
202106	-0.040	114.631	-0.041
202109	-0.070	115.734	-0.071
202112	-0.050	117.630	-0.050

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

VistaGen Therapeutics (NAS:VTGN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.

Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.

VistaGen Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of VistaGen Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

VistaGen Therapeutics Business Description

Industry

Healthcare » Biotechnology NAICS : 325412 SIC : 2834

Comparable Companies

NAS:CLVS NYSE:ZYME XKRX:078160 XKRX:321550 NAS:RLYB NAS:VSTM OSL:ULTI NAS:XERS NAS:KRON NAS:STRO

Traded in Other Exchanges

N/A

Address

343 Allerton Avenue, South San Francisco, CA, USA, 94080

Website

https://www.vistagen.com

VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.

Executives

Saxe Jon S	director	FIRST HORIZON PHARMACEUTICAL CORP 660 HEMBREE PKWY STE 106 ROSWELL GA 30076
Dotson Jerrold Duane	officer: VP, CFO AND SECRETARY	5 CENTERPOINTE DRIVE SUITE 400 LAKE OSWEGO OR 97035
Singh Shawn	director, officer: CHIEF EXECUTIVE OFFICER	C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Snodgrass H. Ralph	director, officer: PRES./CHIEF SCIENTIFIC OFFICER	384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080
Smith Mark Alan	officer: CHIEF MEDICAL OFFICER	343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Mcpartland Mark A.	officer: VP CORPORATE DEVELOPMENT	C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Gin Jerry B	director	343 ALLERTON AVE SOUTH SAN FRANCISCO CA 94080
Underdown Brian J.	director	C/O LUMIRA CAPITAL INVESTMENT MANAGEMENT 141 ADELAIDE ST. WEST, SUITE 770 TORONTO ONTARIO CANADA M5H 3L5 A6 00000
Cunningham Ann Michelle	director	255 N CALDWELL CIRCLE DOWNINGTOWN PA 19335
Rice A. Franklin	officer: VP CORPORATE DEVELOPMENT	384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080
Bonfiglio Gregory A.	director	384 OYSTER POINT BOULEVARD, NO. 8 SOUTH SAN FRANCISCO CA 94080
Platinum Long Term Growth Vii, Llc	10 percent owner	152 WEST 57TH STREET 4TH FLOOR NEW YORK NY 10019
Cato Holding Co	10 percent owner	4364 SOUTH ALSTON AVENUE DURHAM NC 27713
Cato Allen Easley	10 percent owner	4364 SOUTH ALSTON AVENUE DURHAM NC 27713
Jones Stephanie	director, 10 percent owner, officer: PRESIDENT	13834 W. HOYT ROAD RATHDRUM ID 83858

VistaGen Therapeutics Headlines

From GuruFocus

VistaGen Therapeutics Reports New Preclinical Mechanism of Action Data Supporting PH94B's Potential Anti-Anxiety Activity via Peripheral Nasal Neurons without Entry into the Brain

By Marketwired 10-05-2021

VistaGen Therapeutics to Present at the Jefferies London Healthcare Conference

By GuruFocusNews 11-16-2021

VistaGen Therapeutics Expands R&D Team with Appointment of Louis Monti, M.D., Ph.D., Pioneer in the Development of Neuroactive Steroids known as Pherines as Potential Treatments for Anxiety and Depression Disorders, as Vice President, Translational Medici

By PRNewswire 12-01-2020

VistaGen Therapeutics to Report 2021 Fiscal Year End Financial Results, Provide a Business Update and Host Conference Call and Webcast June 29, 2021

By Marketwired 06-25-2021

VistaGen Therapeutics to Report Fiscal Year 2022 First Quarter Financial Results and Host Conference Call and Webcast on August 12, 2021

By Marketwired 08-09-2021

Other Sources